Company intelligence / Profile preview
Myrtelle
Wakefield, Massachusetts, United Statesmyrtellegtx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Myrtelle’s lead candidate, rAAV-Olig001-ASPA, has shown favorable safety and tolerability in a Phase 1/2 trial with eight patients dosed. Early results indicate significant improvements in functional scales and brain white matter content. The company has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA as well as orphan designation from EMA. Initial efficacy data are encouraging for further development of this first-in-class approach targeting oligodendrocytes in children with Canavan disease.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Gene therapy (recombinant adeno-associated virus vectors / rAAV)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
rAAVen Therapeutics – partnership to develop novel AAV vectors for CNS/myelin-based disordersRescue Hearing Inc. – exclusive worldwide licensing agreement to develop a novel gene therapy program targeting DFNB8 genetic hearing loss
Beyond the preview
Go deeper on Myrtelle.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myrtelle.